title: [Erectile dysfunction in diabetic patients].
abstract: Because of its frequency, erectile dysfunction must be systematically screened for in diabetic patients because, according to a survey by the ADIRS-AFD, it has affected 66% of patients for a mean of 6 years, and 77% wish it could be treated. From a physiopathological point of view, erectile disorders in diabetic patients are related to the vascular and neurological complications of diabetes and the various associated risk factors. The treatment to propose is at first iPDE5, although there is a risk of lesser efficacy in a diabetic patient and potential contraindications with the administration of derived nitrates. Intracavernous injections of PGE1 are efficient and safe second line and specialised advice is only required in the case of failure.
authors.affiliation: Endocrinologue sexologue, Lille.
authors.forename: A
authors.initials: A
authors.lastname: Lemaire
authors.forename: B
authors.initials: B
authors.lastname: Alexandre
mesh_terms: D000527:Alprostadil / Q000008:administration & dosage / Q000627:therapeutic use; D000075202:Contraindications; D048909:Diabetes Complications / Q000175:diagnosis / Q000188:drug therapy*; D007172:Erectile Dysfunction / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology*; D006801:Humans; D008297:Male; D012307:Risk Factors; D014665:Vasodilator Agents / Q000008:administration & dosage / Q000627:therapeutic use
chemical_list: D014665:Vasodilator Agents; D000527:Alprostadil